While mutations in IDH genes in Acute Myeloid Leukemia have been associated with poor prognosis, the same mutations are considered as markers of improved prognosis in gliomas, indicating interactions with other proteins or the tumour environment may ultimately influence the role of IDH in tumour pathogenesis. This evidence concerns the gene IDH1 and central nervous system cancer.